Trial Profile
A Phase I, Open-Label, Maximum Tolerated Single-Cycle and Four-Cycle Dose-Finding Study to Evaluation the Safety and Tolerability of 90Y-SMT 487 Administered by Intravenous Infusion to Subjects With Refractory Somatostatin-Receptor Positive Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Sep 2005
Price :
$35
*
At a glance
- Drugs Edotreotide Y-90 (Primary)
- Indications Cancer
- Focus Adverse reactions; Pharmacokinetics
- 08 Sep 2005 New trial record.